According to Teva, its worldwide sales of respiratory drugs, including the Pro-Air albuterol and QVAR beclomethasone inhalers, were down 3% from 2009, to $875 million. Of that amount, $556 million is attributable to sales in the US, where ProAir has a nearly 50% market share and QVAR is the 2nd place inhaled ICS. Read the company’s press release
Teva respiratory drug sales down slightly in 2010
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
